Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.77 |
| ▸ | HTT | P42858 | 1/20 | 0.77 |
| ▸ | RYR2 | Q92736 | 8/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | VHL | P40337 | 1/20 | 0.58 |
| ▸ | ELOC | Q15369 | 1/20 | 0.58 |
| ▸ | ELOB | Q15370 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | METAP1 | P53582 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29596397 | 1.00 | KDM4E (0.77) | KDM4EHTTRYR2ALDH1A1VHL | |
| SCHEMBL7222447 | 0.90 | KDM4E (0.63) | KDM4EHTTRYR2ALDH1A1VHL | |
| SCHEMBL67590 | 0.87 | KDM4E (1.00) | KDM4EHTTRYR2ALDH1A1VHL | |
| SCHEMBL8118067 | 0.83 | RYR2 (0.56) | KDM4EHTTRYR2ALDH1A1KCNH2 | |
| SCHEMBL6366190 | 0.78 | KDM4E (0.82) | KDM4EHTTRYR2ALDH1A1KCNH2 | |
| SCHEMBL56657 | 0.77 | VHL (0.64) | KDM4EHTTALDH1A1VHLELOC | |
| SCHEMBL21038005 | 0.77 | VHL (0.51) | KDM4EHTTRYR2ALDH1A1VHL | |
| SCHEMBL10050688 | 0.77 | KDM4E (0.48) | KDM4EHTTRYR2ALDH1A1VHL | |
| SCHEMBL629534 | 0.76 | RYR2 (1.00) | KDM4EHTTRYR2ALDH1A1KCNH2 | |
| SCHEMBL18537202 | 0.76 | RYR2 (0.50) | KDM4EHTTRYR2ALDH1A1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2499146-B1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO SA (CH) | 2016-09-21 | — | — | EP | disclosed |
| EP-2499146-B1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO SA (CH) | 2016-09-21 | — | — | EP | disclosed |
| US-20160214973-A1 | STORE OVERLOAD-INDUCED CALCIUM RELEASE INHIBITORS AND METHODS FOR PRODUCING AND USING THE SAME | UTI LIMITED PARTNERSHIP (CA) | 2016-07-28 | — | — | US | disclosed |
| US-9073940-B2 | Tricyclic pyrazol amine derivatives | MERCK SERONO SA (CH) | 2015-07-07 | — | — | US | disclosed |
| US-9073940-B2 | Tricyclic pyrazol amine derivatives | MERCK SERONO SA (CH) | 2015-07-07 | — | — | US | disclosed |
| US-9073940-B2 | Tricyclic pyrazol amine derivatives | MERCK SERONO SA (CH) | 2015-07-07 | — | — | US | disclosed |
| US-20120238545-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO SA (CH) | 2012-09-20 | — | — | US | disclosed |
| US-20120238545-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO SA (CH) | 2012-09-20 | — | — | US | disclosed |
| US-20120238545-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO SA (CH) | 2012-09-20 | — | — | US | disclosed |
| EP-2499146-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | Merck Serono S.A. (CH) | 2012-09-19 | — | — | EP | disclosed |
| EP-0539372-A1 | THERAPEUTIC AGENTS | The Boots Company PLC (GB) | 1993-05-05 | — | — | EP | disclosed |
| US-5059609-A | Lipoxygenase inhibitors; leukotriene receptor blockers; psoriasis; antiulcer agents and myocardial infarctions | PFIZER INC. (US) | 1991-10-22 | — | — | US | disclosed |
| WO-1991011448-A1 | THERAPEUTIC AGENTS | THE BOOTS COMPANY PLC (GB) | 1991-08-08 | — | — | WO | disclosed |
| EP-0313295-A2 | Substituted tetralins, chromans and related compounds in the treatment of asthma, arthritis and related diseases | PFIZER INC. (US) | 1989-04-26 | — | — | EP | disclosed |
| US-4282229-A | FOR DIABETIC COMPLICATIONS | PFIZER INC. (US) | 1981-08-04 | — | — | US | disclosed |
| US-4258054-A | ANTIDIABETIC | PFIZER INC. (US) | 1981-03-24 | — | — | US | disclosed |
| US-4210756-A | Tetrahydroquinoline hydantoins for chronic diabetic complications | PFIZER INC. (US) | 1980-07-01 | — | — | US | disclosed |
| US-4209630-A | ANTIDIABETIC AGENTS | PFIZER INC. (US) | 1980-06-24 | — | — | US | disclosed |
| US-4147795-A | ENZYME INHIBITORS | PFIZER INC. (US) | 1979-04-03 | — | — | US | disclosed |
| US-4117230-A | ANTIDIABETIC AGENTS | PFIZER INC. (US) | 1978-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238545-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | PI4KB, MTOR, PI4KA | KDM4E 1093/4885HTT 3430/4885RYR2 4407/4885 |
| US-20160214973-A1 | STORE OVERLOAD-INDUCED CALCIUM RELEASE INHIBITORS AND METHODS FOR PRODUCING AND USING THE SAME | ORAI1, RYR2, CASR | KDM4E 3018/4885HTT 4132/4885RYR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.